Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium animalis subsp. lactis BB-12 and Improved Intestinal Barrier Function

Research synthesisLow evidenceModerate effect4 studies · 4 beneficial · 0 neutral · 0 harmful

Across 4 studies, all reported beneficial effects of Bifidobacterium animalis subsp. lactis BB-12 on intestinal barrier function, with effect sizes ranging from small to moderate (predominantly moderate). Evidence includes a systematic review on colitis disease and in vitro work showing increased transepithelial electrical resistance. No consistent dose or study duration emerges from the available data, and most studies examined animal or cell models rather than healthy humans.

  • Studied populations: colitis disease (human systematic review), DNBS-induced colitis mouse model, Caco-2 cell line (in vitro)

Caveats: Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Most data comes from animal or in vitro models, and human clinical evidence specific to BB‑12 alone is limited.

Generated May 12, 2026
4 of 4 papers
Back to top